C9309 — Injection, onasemnogene abeparvovec-brve, per treatment
C9309 is a HCPCS Level II code for injection, onasemnogene abeparvovec-brve, per treatment. It belongs to the Outpatient Prospective Payment System section. It was terminated on June 30, 2026 and is not valid on new claims.
This code has been terminated
CMS terminated C9309 on June 30, 2026. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for C9309
- Long descriptor
- Injection, onasemnogene abeparvovec-brve, per treatment
- Short descriptor
- Inj onase abepar-brve treat
- Added
- April 1, 2026
- Terminated
- June 30, 2026
- BETOS
- O1E
- Pricing indicator
- 53 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Statute.
Codes adjacent to C9309
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C9309 is not quite right, the correct code is very often within a few positions of it.
- C9301Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9302Injection, zanidatamab-hrii, 2 mgterminated
- C9303Injection, zolbetuximab-clzb, 1 mgterminated
- C9304Injection, marstacimab-hncq, 0.5 mgterminated
- C9305Injection, nipocalimab-aahu, 3 mgterminated
- C9306Injection, telisotuzumab vedotin-tllv, 1 mgterminated
- C9307Injection, linvoseltamab-gcpt, 1 mgterminated
- C9308Injection, carboplatin (avyxa), 1 mgterminated
- C9310Injection, leucovorin calcium (avyxa), 1 mg
- C9349Puraply, and puraply antimicrobial, any type, per square centimeterterminated
- C9352Microporous collagen implantable tube (neuragen nerve guide), per centimeter length
- C9353Microporous collagen implantable slit tube (neurawrap nerve protector), per centimeter length
- C9354Acellular pericardial tissue matrix of non-human origin (veritas), per square centimeter
- C9355Collagen nerve cuff (neuromatrix), per 0.5 centimeter length
- C9356Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (tenoglide tendon protector sheet), per square centimeter
- C9358Dermal substitute, native, non-denatured collagen, fetal bovine origin (surgimend collagen matrix), per 0.5 square centimeters
Questions about C9309
What is HCPCS code C9309?
C9309 is a HCPCS Level II code for injection, onasemnogene abeparvovec-brve, per treatment. It sits in the Outpatient Prospective Payment System section.
Does Medicare cover C9309?
The CMS HCPCS file marks C9309 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
Is C9309 still valid?
No. C9309 was terminated on June 30, 2026 and should not be used on new claims.